News & Events

• April 14, 2021
  

  CPTA Welcomes Triplet Therapeutics Chief Medical Officer as Industry Co-Director

  C-Path’s Critical Path to Therapeutics for the Ataxias Consortium is pleased to announce the appointment of Irina Antonijevic, M.D., Ph.D., as the consortium’s Industry Co-Director. Irina has worked in drug development for over 18 years, with a focus on translational medicine and early development in neuroscience, but also ophthalmology and immunology. She has gained experience......
• April 8, 2021
  

  CP-SCD Announces Pfizer Executive as its First Industry Co-Director

  C-Path’s Critical Path to Sickle Cell Disease Consortium (CP-SCD) is pleased to announce Dr. David Readett of Pfizer as its first Industry Co-Director. David is a pediatrician/pediatric hematologist/oncologist who, prior to transitioning to clinical research in the pharmaceutical industry, spent 18 years in clinical practice, with a focus on clinical care and research for pediatric......
• April 6, 2021
  

  C-Path Welcomes Dr. Ramona Belfiore Oshan as D-RSC Associate Director

  C-Path is pleased to welcome Ramona Belfiore Oshan, Ph.D., as the new Associate Director for its Duchenne Regulatory Science Consortium. D-RSC is currently engaged in several modeling projects of biomarkers and outcome measures, all at different stages in development and regulatory review, as well as development of a platform trial protocol for Duchenne and considering a new patient reported outcome instrument.......
• March 31, 2021
  

  Cures Within Reach Names CURE ID as 2021 Patient Impact Awardee

    Cures Within Reach, a global nonprofit leading the use of repurposing research to help improve patients’ lives, has awarded CURE ID at the FDA and NCATS/NIH as the recipient of the 2021 Golan Christie Taglia Patient Impact Philanthropy Award part of its 2021 Patient Impact Award recipients of the Global Health Repurposing Awards. C-Path’s Cure Drug Repurposing Collaboratory (CDRC),......
• March 31, 2021
  

  Introducing Dr. Alexandre Bétourné, RDCA-DAP Scientific Director

  C-Path is pleased to welcome Alexandre Bétourné, PhD, PharmD, as its new Scientific Director for the Rare Disease Cures Accelerator-Data and Analytics Platform initiative. Dr. Bétourné will work with the RDCA-DAP team to expand its reach into new diseases areas accessing new data and enhancing C-Path’s relationships within the rare disease community. Dr. Bétourné holds......